HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antonio M Risitano Selected Research

Complement 3d Receptors (Complement Receptor 2)

1/2013Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
6/2012The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Antonio M Risitano Research Topics

Disease

36Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
06/2022 - 05/2002
24Hemolysis
06/2022 - 09/2006
20Aplastic Anemia (Anemia, Hypoplastic)
01/2022 - 05/2002
9Anemia
06/2022 - 02/2008
6Fatigue
11/2021 - 09/2006
5COVID-19
02/2021 - 01/2020
5Hemolytic Anemia
12/2014 - 06/2008
4Bone Marrow Failure Disorders
05/2021 - 01/2013
4Hematologic Diseases (Blood Diseases)
01/2018 - 06/2008
3idiopathic Aplastic anemia
01/2022 - 01/2019
3Infections
01/2021 - 11/2015
3Disease Progression
01/2020 - 01/2014
3Cytopenia
01/2019 - 04/2002
3Large Granular Lymphocytic Leukemia
01/2007 - 02/2004
2Chronic Disease (Chronic Diseases)
11/2021 - 09/2006
2Inflammation (Inflammations)
11/2020 - 12/2015
2Thrombotic Microangiopathies
11/2020 - 01/2016
2Thrombocytopenia (Thrombopenia)
01/2019 - 02/2008
2Neoplasms (Cancer)
03/2016 - 09/2006
2Atypical Hemolytic Uremic Syndrome
01/2016 - 06/2015
2Thrombophilia
12/2014 - 01/2013
2Hemoglobinuria
01/2013 - 06/2008
2Graft vs Host Disease (Graft-Versus-Host Disease)
10/2012 - 03/2011
2Leukemia
06/2004 - 11/2002
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
07/2021
1Philadelphia Chromosome
07/2021
1Communicable Diseases (Infectious Diseases)
01/2021
1Tuberculosis (Tuberculoses)
01/2021
1Diamond-Blackfan Anemia (Anemia, Diamond Blackfan)
01/2021
1Thromboinflammation
11/2020
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
11/2020
1Pneumonia (Pneumonitis)
01/2020
1Cytokine Release Syndrome
01/2020
1Lung Injury
01/2020
1Pure Red-Cell Aplasia
11/2019
1Neutropenia
01/2019
1Sickle Cell Anemia (Hemoglobin S Disease)
01/2019
1Membranous Glomerulonephritis (Membranous Nephropathy)
01/2019
1Arthritis (Polyarthritis)
01/2019
1Malaria
10/2016
1Fanconi Anemia (Fanconi's Anemia)
03/2016
1Hereditary Angioedemas
12/2015
1Rare Diseases (Rare Disease)
12/2015

Drug/Important Bio-Agent (IBA)

29Complement System Proteins (Complement)IBA
12/2021 - 09/2006
27eculizumabFDA Link
06/2022 - 09/2006
7Monoclonal AntibodiesIBA
11/2020 - 09/2006
6Biological ProductsIBA
11/2020 - 06/2008
5T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2021 - 05/2002
5Pharmaceutical PreparationsIBA
11/2020 - 06/2015
5Proteins (Proteins, Gene)FDA Link
01/2013 - 04/2002
4Hemoglobins (Hemoglobin)IBA
06/2022 - 07/2008
4L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
05/2021 - 09/2006
4AntigensIBA
01/2021 - 07/2002
4compstatinIBA
11/2020 - 03/2014
4Complement Inactivating AgentsIBA
01/2014 - 09/2006
3Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2022 - 06/2011
3eltrombopagFDA Link
01/2022 - 01/2019
3Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
01/2022 - 08/2010
3Complement Membrane Attack Complex (Membrane Attack Complex)IBA
11/2021 - 10/2011
3CytokinesIBA
11/2020 - 02/2004
3Complement Factor H (Factor H)IBA
01/2019 - 06/2012
2danicopanIBA
12/2021 - 11/2021
2Tyrosine Kinase InhibitorsIBA
07/2021 - 02/2014
2Complement Factor B (Factor B)IBA
05/2021 - 01/2019
2AMY-101IBA
11/2020 - 01/2020
2Interleukin-6 (Interleukin 6)IBA
11/2020 - 01/2020
2Complement C3 (C3 Complement)IBA
11/2020 - 01/2020
2Alemtuzumab (Campath)FDA Link
10/2018 - 01/2012
2anticomplementIBA
01/2018 - 01/2013
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2015 - 01/2012
2Membrane Proteins (Integral Membrane Proteins)IBA
01/2014 - 11/2012
2Complement 3d Receptors (Complement Receptor 2)IBA
01/2013 - 06/2012
2HLA Antigens (Human Leukocyte Antigens)IBA
08/2012 - 05/2002
2thymoglobulinFDA Link
06/2012 - 01/2012
2Prion ProteinsIBA
01/2003 - 07/2002
1pegcetacoplanIBA
06/2022
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
12/2021
1Complement Factor D (Factor D)IBA
12/2021
1Alanine Transaminase (SGPT)IBA
12/2021
1ponatinibIBA
07/2021
1SteroidsIBA
05/2021
1Biomarkers (Surrogate Marker)IBA
05/2021
1ravulizumabIBA
01/2021
1C-Reactive ProteinIBA
11/2020
1Thrombopoietin ReceptorsIBA
06/2019
1Hemin (Panhematin)FDA Link
10/2016
1Dihydrotachysterol (AT 10)IBA
03/2016
1AntibodiesIBA
03/2016
1Busulfan (Busulfex)FDA Link
11/2015

Therapy/Procedure

11Therapeutics
06/2022 - 09/2006
8Hematopoietic Stem Cell Transplantation
01/2022 - 06/2010
5Transplantation
01/2022 - 08/2010
5Stem Cell Transplantation
01/2021 - 01/2011
2Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/2022 - 01/2005
2Homologous Transplantation
07/2021 - 10/2012
1Treatment Delay
01/2022
1Blood Transfusion (Blood Transfusions)
11/2021
1Traction
11/2020
1Erythrocyte Transfusion
01/2019
1Oral Administration
01/2019